Pfizer's Strategy and Innovation Officer Andrew Baum to Leave Company as Part of Strategic Simplification
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a senior strategic advisor role before leaving the company by the end of 2026 as part of its strategic simplification. The move is seen as a continuation of operational streamlining rather than a major strategic shift, according to BMO Capital Markets. Baum, who joined Pfizer in 2024, previously worked at Citi and Morgan Stanley.
Tickers: $PFE
Topics: executive departure Pfizer leadership strategic simplification